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A critical step in the transformation of cells to the malignant state of cancer is the induction of mutations in the DNA of cells
damaged by genotoxic agents. Translesion DNA synthesis (TLS) is the process by which cells copy DNA containing unrepaired
damage that blocks progression of the replication fork. The DNA polymerases that catalyze TLS in mammals have been the topic
of intense investigation over the last decade. DNA polymerase η (Pol η) is best understood and is active in error-free bypass of UV-
induced DNA damage. The other TLS polymerases (Pol ι,P o lκ,R E V 1 ,a n dP o lζ) have been studied extensively in vitro,b u tt h e i r
in vivo role is only now being investigated using knockout mouse models of carcinogenesis. This paper will focus on the studies of
mice and humans with altered expression of TLS polymerases and the eﬀects on cancer induced by environmental agents.
1.Introduction
Tumorigenesis is a multistep process beginning with the
transformation of a single cell by the accumulation of
at least six distinct characteristics. These include inﬁnite
lifespan, resistance to antigrowth signals, resistance to apop-
tosis, autocrine production of growth signals, sustained
angiogenesis, and tissue invasion [1]. Most environmental
carcinogens induce transformation by causing mutations in
the DNA that alter the activity of protooncogenes or tumor
suppressors. These mutations are formed when residual,
unrepaired DNA damage stalls progression of the replication
fork during S phase. Stalled replication forks are most
frequentlyresolved using error-free mechanisms that include
homologous recombination or use of the homologous
nascent strand as a template. Nevertheless, replication may
proceed using the damaged strand as a template in an error-
prone process known as translesion DNA synthesis (TLS).
TLS is deﬁned as the incorporation of a nucleotide across
from DNA damage followed by extension of the potentially
mispaired primer-template, and can be error-free or error-
prone. Cellular commitment to error-free, recombinatorial
damage avoidance or error-prone TLS is modulated by the
molecular switch PCNA (Figure 1). Cells presumably risk
mutations caused by TLS to relieve replication fork blockage
at DNA adducts and to avoid the potential formation of
extremely cytotoxic double strand breaks (DSB). Although
it accounts for less than 10% of all bypass synthesis events in
yeast [2], the frequency of potentially mutagenic TLS may be
as high as 50% in higher eukaryotes [3–5]. The propensity
and mutagenic potential of TLS explain why it is etiologic
in most environmentally-induced cancers and has been the
focus of numerous investigations over the past decade.
TLS is performed by a relatively new category of acces-
sory DNA polymerases. Polymerase η (Pol η), Pol ι,P o lκ,
and REV1 in the Y-family [6]a n dP o lζ in the B-family [7, 8]
are responsible for most TLS in mammalian cells. These
proteins have active sites that are larger and more open than
those of the high-ﬁdelity replicative DNA polymerases (Pol
α, δ,a n dε), allowing accommodation of and synthesis past2 Journal of Nucleic Acids
DNA templates with large, helix-distorting lesions [9]. This
unique ability to synthesize DNA opposite bulky adducts
helps cells avoid double strand breaks associated with
replication fork stalling, but can also lead to mutagenesis by
incorrect base addition. It is important to note that poly-
merases in the Y-family are expressed in all three kingdoms
of life, indicating a critical and evolutionarily conserved role
for these proteins [6]. The obviously conﬂicting roles of
these enzymes in both preventing and promoting genetic
instability are reﬂected in the tight cellular control of the
TLS pathway (Figure 1). Although extensive in vitro studies
have given us a better understanding of their role in the cell,
much less is known about the function of TLS polymerases
in living animals. Limited epidemiological studies have been
conducted to associate single nucleotide polymorphisms
(SNPs) with cancer risk in humans. Knockout mice have
been generated for each gene, and carcinogenesis studies
are published or underway. Importantly, studies in mice
and humans have shown that TLS polymerases, particularly
Pol η, are involved in immunoglobulin gene hypermutation.
Readers are directed to reviews by Reynaud et al. and Diaz
et al. for an exploration of this function of TLS polymerases
[10, 11]. This review will focus on the rapidly progressing
connectionofTLSandcancerresearchinknockoutmiceand
human populations.
2. REV1
REV1 was discovered in budding yeast by the Lawrence
group in 1989 as a component of the Pol ζ complex [17].
ThecatalyticactivityofREV1islimitedtoinsertionofdCMP
across from a template dG [18]. The human homolog was
cloned in 1999 and has the same template-dependent dCMP
transferase catalytic activity on an undamaged template or
an abasic site [19]. One locus used in eukaryotic cells to
measure mutation frequency is HPRT, a gene involved in the
purine salvage pathway. In this forward mutation assay, cells
with loss-of-function mutations in HPRT are resistant to the
drug 6-thioguanine (TG). REV1 is required for carcinogen-
induced HPRT mutagenesis in human cells [20–22], but the
catalytic activity appears to be dispensable for the induction
of UV-induced mutations [23, 24], indicating that this
protein probably plays a structural rather than catalytic role
in UV mutagenesis.
CellsfrommicewithatargeteddeletionoftheBRCA1C-
terminal (BRCT) homology domain of Rev1 (Rev1B/B)h a v e
a reduced UV-induced mutation frequency at the Hprt locus
[25]. However, the animals have a paradoxically decreased
latency of squamous cell carcinoma (SCC) formation and
only marginally reduced p53 mutagenesis in the skin after
UV exposure [26]. Despite Rev1B/B cells showing a moderate
increase in chromatid breaks and exchanges after UV in
vitro [25], comparative genomic hybriziation of UV-induced
SCC and normal skin DNA reveals no increase in the
frequency of gross genomic alterations in Rev1B/B SCC [26].
If point mutations and chromosomal rearrangements are
nearnormallevelsinBRCT-deletedRev1B/B mice,whatisthe
reasonforacceleratedSCCdevelopment?AcuteUVexposure
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Figure 1: Regulation of DNA lesion bypass in Saccharomyces
cerevisiae and humans. Bulky DNA lesions can cause blockage of
replicative polymerases and replication fork stalling. The ubiquitin
conjugase/ubiquitin ligase pair Rad6/Rad18 is recruited to stalled
replication forks where the proteins catalyze monoubiquitylation of
PCNA at lysine 164. TLS proteins such as REV1 and Pol η have
increased aﬃnity for monoubiquitylated PCNA, which facilitates
theirrecruitmentandthecompletion ofTLS.Inyeast,Rad5andthe
MMS2-Ubc13 complex (UBE2V2-UBE2N in humans) can catalyze
polyubiquitylation of PCNA via lysine 63 of ubiquitin, which
blocks TLS and activates error-free damage avoidance. Damage
avoidance includes template switching, during which the nascent
DNA strand from the sister duplex is used as an undamaged
homologous template to replicate past the lesion. Humans express
two Rad5 homologs, SHPRH and HLTF, and both catalyze K-
63-linked polyubiquitylation of PCNA in human cells [12–15].
In yeast, Ubc9-Siz1 can attach the small ubiquitin-like modiﬁer
(SUMO) to lysine 164 of PCNA in a reaction that competes with
Rad6/Rad18-mediated monoubiquitylation. PCNA SUMOylation
at K-164 attracts the helicase Srs2 and prevents error-prone
RAD52-dependent recombination. Reproduced with permission
from Watson et al. [16].
of these Rev1-mutant mice induces enhanced Atr signaling,
senescence, and apoptosis in the skin. However, long-term
low-dose UV exposure causes a mitogenic response, as
evidenced by epidermal hyperplasia, decreased apoptosis,
and increased proliferation of CPD-containing keratinocytes
[26]. Based on literature reports of the etiological role of IL-
6 in carcinogenesis and elevated IL-6 levels in the skin after
a single subtoxic UV dose, the authors conclude that error-
prone TLS of UV-induced DNA damage is responsible for
suppressing the proinﬂammatory, tumor-promoting eﬀects
of UV in the skin. However, more direct immunological
studies are needed to conﬁrm that Rev1 suppresses UV-
induced inﬂammation and tumor suppression.
REV1 has also been implicated in TLS across other
types of DNA lesions. Benzo[a]pyrenediolepoxide (BPDE)
is the primary carcinogenic metabolite of B[a]P and causes
point mutations in a REV1-dependent manner [22, 27].
BPDE-induced Hprt mutations are dramatically decreased
in primary mouse ﬁbroblasts after ribozyme-mediated Rev1-
knockdown. When a plasmid expressing this ribozyme is
delivered to the lungs of A/J mice by aerosol nebulization,Journal of Nucleic Acids 3
Rev1 mRNA is reduced by ∼ %50 in the bronchial epithe-
lium. This targeted gene therapy causes a ∼ %40 reduction
in the lung tumor multiplicity after B[a]P treatment. In
addition, only 73% of ribozyme-treated mice develop lung
adenomas after B[a]P, compared with 100% penetrance in
control animals [28]. This report highlights the potential
for interrupting translesion synthesis as a chemoprevention
strategy.
Although no human disorder involving REV1 deﬁciency
is known, there are 16 SNPs in humans that result in
nonsynonymous amino acid changes. The F257S SNP, which
lies outside of all known functional domains of the protein,
has been associated with an increased risk of squamous
cell carcinoma of the lung in patients who have ever
smoked cigarettes [29]. However, this association remains
controversial [30]. The same F257S SNP was associated
with decreased risk of cervical cancer, and N373S within
the catalytic domain was associated with increased risk of
cervical cancer. Both eﬀects were speciﬁc for squamous
cell carcinoma and not relevant for adenocarcinoma of
the cervix [31]. Although the functional consequences of
these polymorphisms are unknown, these studies support
a role for REV1 in the formation of multiple internal
cancers.
3. Pol η
The study of translesion synthesis in mammals began in
1999 with the discovery of the molecular defect that results
in Xeroderma Pigmentosum (XP) variant syndrome. All
XP patients have dramatically increased susceptibility to
UV-induced skin cancer [32]. Patients in complementation
groups A through G are deﬁcient in nucleotide excision
repair (NER), the major pathway for removal of helix-
distorting lesions, including those induced by UV. However,
the XP variant subset of patients has normal NER activity
[33, 34], yet displays the skin cancer-prone phenotype of
NER-deﬁcient patients. The XP variant mystery persisted for
nearly three decades. Intensive investigations indicate that
after UV-irradiation cells from these patients have diﬃculty
exiting S-phase that is exacerbated by caﬀeine [35, 36]. Fur-
ther, these cells are extremely hypermutable after UV [37]. In
1999, two groups independently discovered that XP variant
patients carry autosomal recessive mutations in POLH, the
human gene coding for Pol η, and that the enzyme can
catalyze error-free DNA synthesis across from a template TT
cyclobutanepyrimidine dimer (CPD)[38–40].Thedramatic
increase in skin cancer risk of XP variant patients could now
be explained by the absence of a critical translesion DNA
polymerase. UV principally induces photoaddition products
between intrastrand adjacent pyrimidines, the most frequent
of which are TT CPD. These lesions block progression
of the replication fork. Data indicate that helicase activity
may continue in spite of the blocked replication complex,
resulting in single-stranded DNA that is rapidly coated with
replication protein A (RPA). This appears to attract the
ubiquitin ligase RAD18, which has binding sites for the
ubiquitin conjugase RAD6, Pol η, and RPA. One target of
ubiquitylation is PCNA. Since Pol η has a ubiquitin binding
domain, Polη is nowthought tobe preferentiallyattractedto
the stalled fork because it is chaperoned directly by RAD18
and binds to the ubiquitylated PCNA (Figure 1)[ 41]. Data
indicatethatPolηthenincorporatesAAacrossfromTTCPD
in the template. In the absence of Pol η, another translesion
polymerase,whichispotentiallyerror-pronewhenbypassing
these common UV-induced lesions, accesses the damaged
template (reviewed in [42, 43]). Generation of Pol η-
knockout mice shows that the highly homologous mouse
Pol η protein functions similarly in UV-induced mutagenesis
and carcinogenesis. Pol η-deﬁcient mice develop squamous
cell carcinoma with 100% penetrance at a UV ﬂuence
that does not cause any tumors in wild-type littermates.
In addition, approximately one-third of heterozygous mice
develop cancer after UV exposure [44]. This raises the
possibility that humans carrying heterozygous mutations in
the POLH gene may have an increased risk of developing
skin cancer. However, this speculation has not been clinically
investigated.
There is evidence that XP variant patients develop
internal cancers faster than Pol η-proﬁcient individuals [45,
46], raising the possibility that Pol η-deﬁciency is involved
in the formation of multiple human cancers caused by
DNA damaging agents other than UV. Six SNPs in POLH
have been found to date that result in nonsynonymous
amino acid substitutions, but their functional signiﬁcance
is unknown. There is a single study evaluating the eﬀects
on cancer risk of POLH polymorphisms. Flanagan and
colleagues found no signiﬁcant changes in coding-region
SNPsofPOLH among40basalcellcarcinomaandsquamous
cell carcinoma patients in a fair-skinned Irish population
[47]. It is clear that larger epidemiological studies of
POLH status are needed to evaluate the eﬀects of POLH
polymorphisms.
4. Pol ι
DNA polymerase ι (Pol ι) was discovered in 1999 as a
novel homolog of Pol η in mammals and is encoded by
the human POLI gene [48]. In vitro studies with puriﬁed
enzyme indicate error-prone TLS function on almost all
substrates examined, perhaps due to the still controversial
ability of Pol ι to incorporate incoming nucleotides using
Hoogsteen base pairing [49, 50]. Exhaustive characterization
of the error-prone replication properties of Pol ι has lent
credibility to the hypothesis that Poli is a candidate gene
for the Pulmonary adenoma resistance 2 (Par2)l o c u si n
mice [51–53]. The Par2 locus was identiﬁed in 1996 by
chromosomal linkage mapping between BALB/cJ and A/J
mouse strains and plays a major role in the relative resistance
of BALB mice versus the A/J strain to developing urethane-
induced lung adenomas [54]. Wang et al. identiﬁed ten
amino acid-substitution polymorphisms between A/J and
BALB mice that produce changes in substrate recognition
of Pol ι; while the enzyme from both strains is functional,
the isoform expressed in BALB mice may be more accu-
rate on certain undamaged templates [52]. These studies4 Journal of Nucleic Acids
suggest that Pol ι acts to suppress urethane-induced lung
adenomas. It has been hypothesized that this activity is
due to the augmentation of base excision repair (BER)
by Pol ι, because the enzyme has 5 deoxyribose phosphate
(dRP) lyase activity and can partially reconstitute the BER-
deﬁciency of Pol β-null cells in vitro [55]. It is possible
thatafterurethane-inducedDNAdamage,whichproduces1,
N6-ethenoadenine adducts [56] that are primarily repaired
by BER [57], Pol ι acts in the gap-ﬁlling step of lesion
repair. If the isoform of Pol ι expressed in A/J mice is
more likely to add the incorrect G opposite a template
T in the gap-ﬁlling step of BER, as was found in vitro
[52], this could explain the increased incidence of lung
adenomas in A/J mice. In support of this hypothesis, nearly
all urethane-induced adenomas in mice have a CAA→CGA
transition in codon 61 of Kras2 [51]. In addition, 129-
derived mouse strains that carry a SNP in codon 27 of
Poli resulting in a severely truncated protein [58] display
extremesensitivitytourethane-inducedlungadenomas[53].
In the absence of Pol ι, it has been hypothesized that another
DNA polymerase, such as Pol β, inserts the incorrect base
during gap ﬁlling in the repair of urethane-induced DNA
d a m a g e .H o w e v e r ,n o r m a lm o u s eP o lι displays extremely
error-prone properties during synthesis opposite all four
undamaged template bases in vitro [58], making it unlikely
to prevent mutations during BER in mice that are Pol ι-
competent. Further studies must be completed to determine
the tumor suppression mechanism of Pol ι in mouse lung
carcinogenesis.
AgrowingbodyofevidencesuggeststhatPol ιisinvolved
in error-prone TLS of UV-induced DNA damage in vivo.
The heightened UV mutagenesis of Pol η-null (XP variant)
human cells has been attributed to TLS by Pol ι [59].
Loss of the functional Poli gene in dermal cells results
in a dramatically reduced UV-induced mutation frequency
at the Hprt locus in both wild-type and Pol η-deﬁcient
mice (Figure 2). Remarkably, however, the decreased UV-
induced mutagenesis observed due to loss of the error-
prone Pol ι from Pol η-deﬁcient mice is associated with
increased cancer risk after UV exposure (Figure 3)[ 60].
This result was conﬁrmed and extended by Ohkumo and
colleagues who showed that Poli−/− m i c ea r em o r el i k e l y
to develop aggressive mesenchymal tumors after UV than
Poli-proﬁcient siblings [61]. These apparently contradictory
ﬁndings speak to the fact that cancer etiology is more
complex than the point mutations scored by the Hprt assay,
and that one cannot use cell biology alone to accurately
predict cancer risk in a TLS model. Indeed, they suggest
a tumor suppressor role for Pol ι that could be separate
from its role as a TLS polymerase prone to induce single
base-substitution mutations. It is also possible that Pol ι
is error-free when bypassing a minor UV adduct, or that
it is involved in error-free BER of the minimal oxidative
damageinducedbyUVBusedinthesestudies[62],butmore
detailed experiments must be performed to evaluate these
possibilities.
The role of Pol ι in the induction of cancer induced
by other carcinogens has not been systematically studied to
date. It is interesting to note that Newcomb et al. found
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Figure 2: Frequency of 6-thioguanine-resistant (TG
r) clones as
a function of survival after UV irradiation. Cells were plated
on three 150-mm-diameter dishes at a density of 104 cm−2 to
determine mutant frequency or at cloning density to determine
survival. After attachment, plates were irradiated with UV ﬂuences
to yield 20%−40% survival. The actual survival in the mutagenesis
experiments was determined by refeeding the survival plates at
one week and staining with crystal violet after two weeks. Percent
survival for each UV ﬂuence was corrected for replating and
p l o t t e do nt h ex-axis. The corresponding mutant frequency at each
survival is plotted on the y-axis. Each point represents the mean of
three independent dishes at the indicated survival, ±1SD.Mutant
frequency at the Hprt locus is deﬁned as the number of TG
r clones
per million clonable cells. Each data point represents independent
experiments in which 2-4 × 106 surviving cells were selected after
UV irradiation and an 8- to 9-day expression period. The data have
been corrected for cloning eﬃciency on the day of selection, and
the spontaneous background mutant frequency (1×10
−5)h a sb e e n
subtracted. The arrows indicate the reduction in mutant frequency
when Polι is disrupted in the Pol η-deﬁcient background (larger
arrow) and in the Pol η-proﬁcient background (smaller arrow).
Reproduced with permission from Dumstorf et al. [60].
that Pol ι-deﬁcient 129 mice are resistant to γ-irradiation-
induced thymic lymphoma but sensitive to methylating
agent-inducedthymiclymphoma[63].γ-Irradiationinduces
DNA strand breaks and oxidative damage, and Pol ι is
known to protect cells from oxidative stress [64]. It is
thereforepossible thatincreasedcelldeathafterγ-irradiation
protects Poli−/− 129 mice from lymphomagenesis. However,
Pol ι does not aﬀect the sensitivity of Pol β-null cells to
methylating agents [65], so the sensitivity of 129 mice to
thymic lymphoma induced in this way is still unexplained.
There is no known human disorder involving deﬁciency
for Pol ι.H o w e v e r ,P o l ι is overexpressed in some lung
cancer cell lines [52]a sw e l la si np r i m a r yh u m a ng l i o m a s
[66]. The T706A SNP was found to increase the risk of
adenocarcinoma and squamous cell carcinoma of the lung
in persons < 61 years of age [29]. However, this association
was not conﬁrmed by another independent study [67]
and failed to show signiﬁcance in a meta-analysis [68].Journal of Nucleic Acids 5
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Figure 3: UV light-induced skin cancer in mice. Mice were shaved
once per week and irradiated three times per week with 3.75kJ/m2
for 20 weeks or until the ﬁrst skin tumor arose. Mice were inspected
weekly for the development of skin tumors. All 12 homozygous
Polh knockout mice (open diamonds) developed skin tumors by
18 weeks, while all 12 Polh−/−Poli−/− mice (open circles) developed
skin tumors by 13 weeks. This Poli-dependent decrease in tumor
latency is highly signiﬁcant (P<. 0002). No diﬀerence was found
in the histological analysis of skin tumors among the groups.
Reproduced with permission from Dumstorf et al. [60].
Another SNP in human POLI, F532S, is associated with
prostate cancer patients whose tumors display TMPRSS2-
ERG fusion with a highly signiﬁcant odds ratio of 4.6 [69].
The protooncogenic transcription factor ERG was identiﬁed
as the most frequently overexpressed gene in human prostate
cancers[70],and fusionwith the androgen-responsive serine
protease TMPRSS2 by chromosomal rearrangement was
found in >90% of ERG-overexpressing cases [71]. Threonine
706 and serine 532, the two residues altered by these SNPs
in Pol ι, are located in the noncanonical ubiquitin-binding
motifs UBM2 and UBM1, respectively [72]. These two
polymorphisms could therefore aﬀect binding of Pol ι to
ubiquitylated PCNA, which is required for its recruitment to
stalled replication forks following DNA damage. In the case
of prostate cancer, the F532S variant of Pol ι may promote
chromosomal instability by causing replication fork stalling
and double-strand break (DSB) formation. DSB formed in
this way could promote cellular transformation by causing
chromosomal rearrangements that place the protooncogene
ERG under control of the androgen-responsive promoter
elements of TMPRSS2 and lead to ERG-overexpression as is
found in many prostate cancers [71]. Evidence supports the
suppression of skin and lung cancers by Pol ι in humans and
mice, and new studies suggest that other cancers could be
aﬀected by this protein, making it a promising candidate for
future investigation.
5. Pol κ
The fourth member of the Y-family is DNA polymerase
κ.P o lκ performs faithful TLS of BPDE-induced DNA
damage in vitro by inserting dC opposite a template BPDE-
adducted G [73–75]. Pol κ is required for recovery from
a novel BPDE-induced intra-S phase checkpoint, and the
protein relocalizes to stalled replication forks after BPDE-
induced DNA damage [76, 77]. Polk−/− mouse embryonic
ﬁbroblasts(MEFs)showpersistentS-phasearrestafterBPDE
exposure,whichresultsinincreasedDSBformationatstalled
replication forks and increased toxicity in cells without
functional Pol κ [77]. Avkin and colleagues measured TLS
eﬃciency and ﬁdelity in Polk−/− MEFs using a shuttle vector
technique. TLS eﬃciency on a plasmid containing a site-
speciﬁc BPDE-N2-dG adduct is reduced nearly threefold in
Polk−/− MEFs, and mutagenic TLS is increased from 29%
to 50% in knockout cells, supporting a role for Pol κ in
the eﬃcient and error-free bypass of BPDE DNA damage
[78]. siRNA-mediated POLK-knockdown also reduces the
eﬃciency of TLS past BPDE-N2-dG in human U2OS cells
[79]. This body of evidence suggests that Pol κ could have
an important role in cancers caused by bulky chemical
carcinogens like BPDE. Pol κ has also recently been linked to
nucleotide excision repair. Polk
−/− MEFs have reduced levels
of NER of UV damage, including reduced repair synthesis
and removal of 6-4 photoproducts after UV. Both of these
phenotypes are largely corrected by expressing wild-type
Pol κ, but not a catalytically inactive mutant [80]. Pol κ
carries out NER repair synthesis and is recruited to sites of
NER through its interaction with XRCC1 and ubiquitylated
PCNA [81]. These remarkable studies highlight the ability
of TLS polymerases to function in multiple cellular path-
ways and the likelihood that Polk plays an important role
in preventing DNA damage-induced carcinogenesis. While
Polk-knockout mice have been generated [82, 83] and show
increased spontaneous mutagenesis in kidney, liver, and lung
[84], no cancer studies have yet been reported using these
models.
Pol κ is overexpressed in ∼70% of nonsmall cell lung
cancers (NSCLC) examined [85], and this overexpression
correlates with mutation status of TP53 [86]w h i c hi s
itself an indicator of poor prognosis [87]. In addition,
POLK promoter activity is increased in TP53
−/− cells, and
p53 protein suppresses POLK promoter activity in vitro.
These reports suggest that Pol κ overexpression in NSCLC
could be secondary to loss of functional p53, but the
correlation between these two events must be investigated
to rule out an etiological role for Pol κ in lung cancer.
Much stronger epidemiological evidence shows that Pol κ
is overexpressed in gliomas. Multivariate analysis indicates
thatPolκoverexpressionisanindependentprognosticfactor
for the assessment of glioma patient outcomes (Figure 4)
[66]. Although the potential role of Pol κ in the etiology
of brain tumors is unclear, Pol κ is clearly a candidate for6 Journal of Nucleic Acids
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Figure 4: Immunohistochemical analysis of Pol κ,P o lι, and Pol η expression in primary glioma tissues (g) and normal brain tissues (n).
Paraﬃn-embedded tissue microarrays comprising 104 primary glioma specimens from WHO grades I-IV were stained for Pol κ,P o lι,o r
Pol η.R e p r e s e n t a t i v ei m a g e so fP o lκ,P o lι, and Pol η expression: Aa, Ab, Ba, Bb, Ca, and Cb, normal brain tissue; Ac, Ad, Bc, Bd, Cc, and
Cd, pilocytic astrocytoma (WHO grade I); Ae, Af, Be, Bf, Ce, and Cf, diﬀu s ea s t r o c y t o m a( W H Og r a d eI I ) ;A g ,A h ,B g ,B h ,C g ,a n dC h ,
anaplastic astrocytomas (WHO grade III); Ai, Aj, Bi, Bj, Ci, and Cj, glioblastoma multiforme (WHO grade IV); magniﬁcation: X100 (Aa, Ac,
A e ,A g ,A i ,B a ,B c ,B e ,B g ,B i ,C a ,C c ,C e ,C g ,a n dC i )a n dX 4 0 0( A b ,A d ,A f ,A h ,A j ,B b ,B d ,B f ,B h ,B j ,C b ,C d ,C f ,C h ,a n dC j ) .R e p r o d u c e d
with permission from Wang et al. [66].
investigationofcancerriskandchemopreventionofmultiple
tumor types.
6. Pol ζ
The human homolog of yeast DNA Polymerase ζ is required
for mutagenesis by UV, BPDE, and other carcinogens [7, 88].
Pol ζ belongs to the B-family of DNA polymerases and
contains a large catalytic subunit encoded by the REV3
gene in humans [7] along with the much smaller regulatory
protein REV7 [89]. Early investigations in Saccharomyces
cerevisiae showed that rev3 mutant strains have reduced
rates of spontaneous mutation [90], indicating that Pol ζ
is involved in the mutagenic processing of spontaneous
and UV-induced mutations. Studies in mammalian cells
indicate that Pol ζ has a role in both repair of double
strand breaks and base substitution mutagenesis, the latter
likely involving extension of mispaired primer termini after
initial TLS by another polymerase [91, 92]. Pol ζ is the only
TLS polymerase required for development, and complete
Rev3-knockout results in mitotic catastrophe and lethality
at mouse embryonic day 10.5 [93–95]. However, conditional
Rev3-knockout mice have been generated and are viable and
fertile.WhileRev3-deﬁciencyaloneisinsuﬃcienttopromote
cancer formation, conditional Rev3 knockout accelerates the
spontaneous formation of lymphoma in Trp53
−/− mice. In
humans, REV3 gene expression is reduced by twofold in
40 of 74 (54%) colon carcinomas compared to matched
normal tissue [96]. However, normal expression is found
in much smaller sample sets of gastric, colon, lung, and
renal cancers [97], and the gene is not mutated in primary
tumors or cell lines from breast and colon cancers [89]. The
expression levels of REV3 in human cancers, particularly
colon carcinoma, must be revisited using larger sample sizes
to draw ﬁrm conclusions about the correlation of gene
expression and cancer progression. No studies are published
investigating the 25 nonsynonymous SNPS in human REV3,
but the possibility exists that functional changes in human
Pol ζ could alter the risk of cancer formation.Journal of Nucleic Acids 7
7. Conclusions
The importance of translesion DNA synthesis in preventing
human cancer is well understood from the example of
XP variant, in which patients lacking the Y-family DNA
polymerase η are prone to develop UV-induced skin cancers
due to an extremely hypermutable phenotype. However,
we understand very little about how the other polymerases
involved in TLS aﬀect human health and cancer risk.
Recently developed mouse models have so far provided
conﬂicting results; ribozyme-mediated knockdown of total
Rev1 and removal of the BRCT domain both result in
reduced mutagenesis by BPDE or UV, respectively. As
expected, when Rev1 mRNA is knocked down using the
same ribozyme delivered to the lungs of mice, multiplicity
of B[a]P-induced lung adenomas decreases [28]. In contrast,
Rev1 BRCT-null mice develop UV-induced squamous cell
carcinomas faster than wild-type controls [26]. In a similarly
paradoxical ﬁnding, mice lacking both Pol η and Pol ι have
decreased UV-induced mutations in their dermal ﬁbroblasts
and accelerated development of squamous cell carcinoma
after UV treatment compared to Pol ι-proﬁcient animals
[60]. While it is understood that the mutations induced by
these polymerases are etiological in many environmentally-
induced cancers, it is clear from these studies that simply
blocking TLS is not suﬃcient to reduce cancer risk, and
in fact may cause an acceleration of carcinogenesis. More
detailed studies are needed using existing mouse models to
determine the eﬀects of TLS polymerase activity on cancer
development after diverse carcinogen exposures. In addition,
molecular epidemiological studies must be conducted to
evaluate the functional consequences of the many nonsyn-
onymousSNPsinTLSpolymerasegenes,someofwhichhave
already been associated with cancer risk or protection. After
a decade of intense research, there are still critical gaps in our
understandingoftheroleofTLSinhumanhealthandcancer
risk.
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